aTyr Pharma, Inc. - Common Stock (ATYR)

Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.

ATyr Pharma's stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung function and steroid withdrawal rates.

Investors braced for imminent Phase 3 EFZO-FIT trial results of efzofitimod, with analysts calling it a key inflection point.

The next couple of weeks could reveal a great deal about this stock's prospects.

The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

In today's session, there are notable price gaps in the US markets on Friday. Take a closer look at the stocks that are gap up and gap down.